Buenos Aires, 2 May 2023. Last April, Laboratorios Poen S.A.U. (“Poen”) and Grupo Dromex signed an agreement through which Poen acquired Dromex Biotech S.A. This acquisition will allow Poen to expand its installed capability by incorporating the new plant located in the Ezeiza industrial park and improve the working capacity of its teams, complying with the highest production standards and with the demands of the national and international health authorities.
Poen, part of Megalabs group, is a leading company dedicated to elaborating state-of-the-art sterile ophthalmic products, such as solutions, suspensions, nanoemulsions, gels, and ointments. The company also owns divisions focused on nutrition and contact lens care products. Dromex Biotech will enter into synergy with Poen’s plant dedicated to eye drops production operating in the Floresta neighborhood in Buenos Aires.
Counsel to Poen
Beccar Varela: partners Ramón I. Moyano, Carolina Serra and Ana Andrés, and senior associate Luciana Liefeldt.
Megalabs’ in-house counsel: Juan Pedro Quagliata.
Counsel to Dromex
Naveira Truffat Martínez Abogados: partners Oscar Martínez and Agustín Ferrari, Astrid Nottebohm and Lorenzo Tirri.